Trevi Therapeutics, Inc. (TRVI) News

Trevi Therapeutics, Inc. (TRVI): $1.98

-0.05 (-2.46%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter TRVI News Items

TRVI News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest TRVI News From Around the Web

Below are the latest news stories about Trevi Therapeutics Inc that investors may wish to consider to help them evaluate TRVI as an investment opportunity.

Trevi Therapeutics to Present at 2021 BIO Digital Conference

NEW HAVEN, Conn., June 9, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) to treat serious neurologically mediated conditions,

PR Newswire | June 9, 2021

BMO Capital Thinks Trevi Therapeutics Stock is Going to Recover

In a report released today, Gary Nachman from BMO Capital assigned a Buy rating to Trevi Therapeutics (TRVI), with a price target of The post BMO Capital Thinks Trevi Therapeutics Stock is Going to Recover appeared first on Smarter Analyst .

Smarter Analyst | May 14, 2021

Trevi Therapeutics Announces First Quarter 2021 Financial Results and Business Update

NEW HAVEN, Conn., May 13, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) to treat serious neurologically mediated conditions,

PR Newswire | May 13, 2021

Is it time to Buy before this weeks earning report Trevi Therapeutics (NASDAQ:TRVI)

Earnings results for Trevi Therapeutics , Analyst Opinion on Trevi Therapeutics , Earnings and Valuation of (NASDAQ:TRVI), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post Is it time to Buy before this weeks earning report Trevi Therapeutics (NASDAQ:TRVI) appeared first on .

Stock Market Daily | May 12, 2021

Trevi Therapeutics to Report Q1 2021 Financial Results on May 13

Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will host a conference call and live audio webcast on Thursday, May 13 at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended March 31, 2021.

Yahoo | May 6, 2021

Trevi Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference

NEW HAVEN, Conn., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will participate in a virtual fireside chat, as well as host virtual investor meetings, at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021. Presentation Time: 4:20 p.m. ET A live webcast of the virtual fireside chat can be accessed by visiting ‘News & Events’ in the ‘Investors & News’ section on the Company’s website at www.trevitherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company’s website following the conference. ...

Yahoo | February 18, 2021

Trevi Therapeutics Announces Third Quarter 2020 Financial Results and Business Update

PRISM Trial of Haduvio™ for Severe Pruritus in Patients with Prurigo Nodularis  Exceeds Halfway Enrollment MilestonePhase 2 Chronic Cough Trial in Patients with IPF Enrolled First New Subject Post-COVID-19 RestrictionsCash Position Expected to Fund Operations into the First Half of 2022NEW HAVEN, Conn., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced financial results for the quarter ended September 30, 2020, as well as business updates.“We are pleased with the continued progress of our clinical development programs,” said Jennifer L. Good, President and CEO of Trevi Therap...

Yahoo | November 11, 2020

Trevi Therapeutics to Present at Stifel Healthcare Conference

NEW HAVEN, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will present a Company overview, as well as host virtual investor meetings, at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020. Presentation Time: 10:00 a.m. ETA live webcast of the presentation can be accessed by visiting ‘News & Events’ in the ‘Investors & News’ section on the Company’s website at www.trevitherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company’s website following the conference.The Company’s corporate presenta...

Yahoo | November 10, 2020

Trevi Therapeutics to Report Q3 2020 Financial Results on November 11

Conference Call and Webcast to be Held at 4:30 p.m. ETNEW HAVEN, Conn., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on November 11, 2020, to provide a corporate update and review the Company’s financial results for the third quarter ended September 30, 2020. To participate in the live conference call by phone, please dial (866) 360-5746 (domestic) or (602) 563-8605 (international) and provide access code 9375955. A live audio webcast will be accessible from the ‘Investors & News’ section ...

Yahoo | November 4, 2020

Is Trevi Therapeutics (NASDAQ:TRVI) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | November 3, 2020


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4891 seconds.